Several in situ vaccination regimens of in vivo HCC models have reported additive effects with checkpoint blockade, e.g. for radiotherapy (80), TLR7/8 agonists (77) and TLR9 agonists (190). The gene discussed is TLR9; the disease is hepatocellular carcinoma.